Cellectis SA (CLLS) Stock Price, Quote, News & History

CLLSNASDAQ
$3.42
0.237.21%
Last update: Aug 25, 7:49 AM
$3.41
0.226.9%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-41.63M
Investing Cash Flow (TTM)
31.56M
Financing Cash Flow (TTM)
-16.55M
Free Cash Flow (TTM)
-44.98M
Capital Expenditure (TTM)
-3.35M
Net Change in Cash (TTM)
-26.62M

Analyst Trends and Forecast

0
0
0
0
Apr
1
May
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.5
Strong Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$241.92M
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
5.61
PB Ratio (TTM)
7.75
Earnings Yield % (TTM)
-20.38%
Earnings Yield % (FWD)
-
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$0.41

Company Debt

Total Debt
$53.98M
LT Debt
$52.66M
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-$16.36M
Total Cash
$35.59M
Debt to Equity
2.06
Issuance of Debt (TTM)
-$16.36M
Repayment of Debt (TTM)
-$16.36M

Key Statistics

Open
$3.33
Close
$3.42
Volume / Avg.
15.89K / 29.95K
Day Range
$3.31 - $3.47
52 Wk Range
2.35 - 5.48
Market Cap
$343.39M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
62
Short Interest
0.54%
Days to Cover
22.03

About

Sector
Health Care
Industry
Biotechnology
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the fi...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Cellectis (CLLS) stock?

A

You can purchase shares of Cellectis (NASDAQ:CLLS) through any online brokerage.

View our list of the best stock brokerages

Q

What is the forecast, or price target, for Cellectis (CLLS) stock?

A

Cellectis has a consensus price target of $8.33.

Q

What is the current price for Cellectis (CLLS)?

A

The stock price for Cellectis (NASDAQ: CLLS) is $3.41 last updated August 25, 2026 at 7:49 AM EDT.

Q

Does Cellectis (CLLS) pay a dividend?

A

There are no upcoming dividends for Cellectis.

Q

When is Cellectis (NASDAQ:CLLS) reporting earnings?

A

Cellectis does not have any upcoming earnings scheduled.

Q

Is Cellectis (CLLS) going to split?

A

There is no upcoming split for Cellectis.

Q

What sector and industry does Cellectis (CLLS) operate in?

A

Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.